<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-30096" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Thrombocytopenia in Pregnancy</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mangla</surname>
            <given-names>Ankit</given-names>
          </name>
          <aff>Case Western Reserve University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hamad</surname>
            <given-names>Hussein</given-names>
          </name>
          <aff>University Hospitals/Case Western Univ</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ankit Mangla declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hussein Hamad declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>30</day>
          <month>11</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-30096.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Thrombocytopenia, a platelet count under 150 x 10<sup>9</sup>/L, is pregnancy's second most common hematological abnormality. This CME activity reviews the presentation, diagnosis, and management of thrombocytopenia in pregnancy and discusses the role of the interprofessional team in managing pregnant women with low platelet counts. The reader will also learn about the role of other specialists, especially hematologists, in managing pregnant women with thrombocytopenia, the etiologies of thrombocytopenia in pregnancy, and how to manage them.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the etiology of thrombocytopenia in pregnancy.</p></list-item><list-item><p>Determine&#x000a0;the evaluation of thrombocytopenia in pregnancy.</p></list-item><list-item><p>Apply the treatment and management options available for thrombocytopenia in pregnancy.</p></list-item><list-item><p>Communicate&#x000a0;the importance of improving care coordination amongst the interprofessional team to enhance the delivery of care for patients with thrombocytopenia in pregnancy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30096&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30096">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-30096.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Thrombocytopenia, a platelet count under 150 x 10<sup>9</sup>/L, is pregnancy's second most common hematological abnormality.<xref ref-type="bibr" rid="article-30096.r1">[1]</xref><xref ref-type="bibr" rid="article-30096.r2">[2]</xref>&#x000a0;The International Working Group (IWG) adopted a lower threshold of platelets, 100 x 10<sup>9</sup>/L, to define immune thrombocytopenia, which is observed in less than 1% of all pregnancies.<xref ref-type="bibr" rid="article-30096.r1">[1]</xref><xref ref-type="bibr" rid="article-30096.r3">[3]</xref><xref ref-type="bibr" rid="article-30096.r2">[2]</xref> Thrombocytopenia in pregnancy occurs due to obstetric conditions (like gestational thrombocytopenia, pre-eclampsia/eclampsia) or secondary to systemic disorders (thrombocytopenic thrombotic purpura, immune thrombocytopenia).<xref ref-type="bibr" rid="article-30096.r4">[4]</xref><xref ref-type="bibr" rid="article-30096.r5">[5]</xref> For the present discussion, the approach to thrombocytopenia has its basis in the trimester in which the thrombocytopenia develops and the etiology of the thrombocytopenia. This division helps in understanding the workup and guiding management. Even though thrombocytopenia is a common abnormality in pregnancy, it seldom leads to life-threatening complications by itself. The management of thrombocytopenia&#x000a0;focuses on the underlying cause. Platelet transfusion is usually not required to achieve&#x000a0;a particular goal and is only for bleeding patients.<xref ref-type="bibr" rid="article-30096.r1">[1]</xref><xref ref-type="bibr" rid="article-30096.r4">[4]</xref><xref ref-type="bibr" rid="article-30096.r6">[6]</xref> Local hospital policies govern the goal of platelet counts and are quite variable between institutions. Nevertheless, a hematologist must be involved in the management of thrombocytopenia in pregnancy, especially if the platelet count drops below 70 x 10<sup>9</sup>/L or if a&#x000a0;coexistent bleeding disorder is either encountered or suspected.</p>
      </sec>
      <sec id="article-30096.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Thrombocytopenia in pregnancy happens secondary to&#x000a0;many etiologies,&#x000a0;differing in their pathophysiology and presentation. A summary of possible etiologies is listed here:</p>
        <list list-type="order">
          <list-item>
            <p>Gestational thrombocytopenia&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Immune thrombocytopenia</p>
          </list-item>
          <list-item>
            <p>Thrombotic microangiopathy (TMA): Due to differences in management, TMA in pregnancy divides into pregnancy-specific TMA and non-pregnancy-specific TMA.
<list list-type="order"><list-item><p>Pregnancy specific TMA
<list list-type="bullet"><list-item><p>Pre-eclampsia (PEC):&#x000a0;</p></list-item><list-item><p>Hemolysis, elevated liver enzymes, low platelets (HELLP) syndrome</p></list-item><list-item><p>Acute fatty liver of pregnancy (AFLP)</p></list-item></list>
</p></list-item><list-item><p>TMA not specific to pregnancy
<list list-type="bullet"><list-item><p>Thrombotic thrombocytopenic purpura (TTP)</p></list-item><list-item><p>Atypical hemolytic-uremic syndrome (HUS)</p></list-item></list>
</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Disseminated intravascular coagulation (DIC)</p>
          </list-item>
          <list-item>
            <p>Hereditary thrombocytopenia (HT): Further classified according to the size of the platelet, genetic defect, and inheritance pattern (WAS gene, HOXA 11 gene, MYH9 disorders, etc)<xref ref-type="bibr" rid="article-30096.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p>Others:
<list list-type="order"><list-item><p>Bone marrow failure syndromes
<list list-type="bullet"><list-item><p>Aplastic anemia</p></list-item><list-item><p>Myelodysplastic syndrome (MDS),</p></list-item><list-item><p>Myeloproliferative neoplasms (MPN),</p></list-item><list-item><p>Leukemia/lymphoma&#x000a0;</p></list-item><list-item><p>Marrow infiltrative disorders</p></list-item></list>
</p></list-item><list-item><p>Paroxysmal nocturnal hemoglobinuria (PNH),</p></list-item><list-item><p>Drug-induced thrombocytopenia,</p></list-item><list-item><p>Type IIB von Willebrand disease (VWD).</p></list-item><list-item><p>Heparin-induced thrombocytopenia (HIT)&#x000a0;<xref ref-type="bibr" rid="article-30096.r4">[4]</xref><xref ref-type="bibr" rid="article-30096.r8">[8]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <p>It is also worthwhile to distribute the etiology of thrombocytopenia according to the trimester and the platelet count.<xref ref-type="bibr" rid="article-30096.r4">[4]</xref></p>
        <p>
<bold>First Trimester</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Immune thrombocytopenia (ITP) (most common)</p>
          </list-item>
          <list-item>
            <p>Hereditary thrombocytopenia (HT)</p>
          </list-item>
          <list-item>
            <p>Others <italic toggle="yes">(Please see above for a detailed list)</italic></p>
          </list-item>
          <list-item>
            <p>Thrombotic microangiopathy (TMA)</p>
          </list-item>
        </list>
        <p>
<bold>Second Trimester</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Platelet count greater than 100 x 10/L</bold>
<list list-type="order"><list-item><p>Gestational thrombocytopenia</p></list-item><list-item><p>ITP</p></list-item><list-item><p>Pre-eclampsia/ HELLP</p></list-item><list-item><p>HT/Others/TMA</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Platelet count under 100 x 10/L</bold>
<list list-type="order"><list-item><p>ITP (most common)</p></list-item><list-item><p>HT</p></list-item><list-item><p>Pre-eclampsia/HELLP</p></list-item><list-item><p>Others</p></list-item><list-item><p>Gestational thrombocytopenia&#x000a0;</p></list-item><list-item><p>TMA</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Third Trimester</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Platelet count more than 100 x 10/L</bold>
<list list-type="order"><list-item><p>Gestational Thrombocytopenia (most common)</p></list-item><list-item><p>Pre-eclampsia/ HELLP (second most common)</p></list-item><list-item><p>Others/TMA/ITP/HT</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Platelet count less than 50 x 10/L</bold>
<list list-type="order"><list-item><p>Pre-eclampsia/ HELLP (most common)</p></list-item><list-item><p>ITP</p></list-item><list-item><p>Others</p></list-item><list-item><p>TMA</p></list-item><list-item><p>Gestational thrombocytopenia/HT</p></list-item></list>
</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30096.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Thrombocytopenia affects 7 to 11% of all pregnancies. However, less than 1% of pregnancies experience a drop in platelet count below 100 x 10<sup>9</sup>/L.<xref ref-type="bibr" rid="article-30096.r1">[1]</xref><xref ref-type="bibr" rid="article-30096.r5">[5]</xref><xref ref-type="bibr" rid="article-30096.r6">[6]</xref> It is the second most common hematologic abnormality in pregnancy after anemia.<xref ref-type="bibr" rid="article-30096.r1">[1]</xref>&#x000a0;Overall, gestational thrombocytopenia&#x000a0;is the most common cause of low platelets in pregnancy, followed by pre-eclampsia (20% of patients) and ITP (1 to 4%).<xref ref-type="bibr" rid="article-30096.r6">[6]</xref><xref ref-type="bibr" rid="article-30096.r9">[9]</xref> The other etiologies mentioned in the previous section (TMA, HT, DIC, HT, and other causes) rarely cause thrombocytopenia in pregnancy (less than 1%).<xref ref-type="bibr" rid="article-30096.r6">[6]</xref><xref ref-type="bibr" rid="article-30096.r4">[4]</xref> Although the rare causes of thrombocytopenias do not constitute more than 1% of pregnant patients with low platelet counts, they often designate severe conditions that contribute significantly to maternal morbidity and mortality.</p>
        <list list-type="order">
          <list-item>
            <p>Gestation thrombocytopenia: Overall, gestational thrombocytopenia is the reason for low platelets in nearly 75% of pregnancies presenting with thrombocytopenia. It is the most common cause of low platelets in the third trimester of pregnancy.<xref ref-type="bibr" rid="article-30096.r6">[6]</xref><xref ref-type="bibr" rid="article-30096.r4">[4]</xref></p>
          </list-item>
          <list-item>
            <p>Immune thrombocytopenia (ITP): ITP is the most common cause of low platelets in the first trimester of pregnancy. It affects 1 to 4% of all pregnancies and 1 to 2 per 1000 pregnancies each year.<xref ref-type="bibr" rid="article-30096.r10">[10]</xref><xref ref-type="bibr" rid="article-30096.r4">[4]</xref> Approximately two-thirds of women have ITP diagnosed&#x000a0;before the start of pregnancy.<xref ref-type="bibr" rid="article-30096.r11">[11]</xref></p>
          </list-item>
          <list-item>
            <p>Thrombotic microangiopathy (TMA):&#x000a0;
<list list-type="order"><list-item><p>Pregnancy specific TMA
<list list-type="bullet"><list-item><p>Pre-eclampsia (PEC): Throughout the world, PEC affects 2% to 8% of all pregnancies and&#x000a0;accounts for 20% of patients developing thrombocytopenia in pregnancy.<xref ref-type="bibr" rid="article-30096.r6">[6]</xref><xref ref-type="bibr" rid="article-30096.r12">[12]</xref>&#x000a0;Thrombocytopenia in a patient with PEC occurs&#x000a0;primarily in the second and third trimester of pregnancy and occurs in up to&#x000a0;50% of pre-eclamptic women. Rarely, pre-eclampsia can also occur within the first week post-partum.<xref ref-type="bibr" rid="article-30096.r4">[4]</xref><xref ref-type="bibr" rid="article-30096.r9">[9]</xref></p></list-item><list-item><p>HELLP (Hemolysis, elevated liver enzymes, low platelets): HELLP syndrome affects 0.2 to 0.8% of all pregnancies. However, it is one of the rare causes of thrombocytopenia in pregnancy.<xref ref-type="bibr" rid="article-30096.r13">[13]</xref> It is associated with pre-eclampsia in up to 70 to 80% of patients.<xref ref-type="bibr" rid="article-30096.r13">[13]</xref>&#x000a0;Up to 20% of cases of HELLP are identified 24 to 48 hours postpartum, where thrombocytopenia may persist for up to 4 days after delivery.<xref ref-type="bibr" rid="article-30096.r9">[9]</xref></p></list-item><list-item><p>Acute fatty liver of pregnancy (AFLP): It is a rare cause of thrombocytopenia in pregnancy, which is estimated to affect 1 in 5000 to 20,000 pregnancies.<xref ref-type="bibr" rid="article-30096.r14">[14]</xref><xref ref-type="bibr" rid="article-30096.r15">[15]</xref>&#x000a0;</p></list-item></list>
</p></list-item><list-item><p>TMA not specific to pregnancy: These are amongst the rarest causes of thrombocytopenia in pregnancy.
<list list-type="bullet"><list-item><p>Thrombotic thrombocytopenic purpura (TTP): TTP is estimated to affect 1 in 200,000 pregnancies, but 10 to 30% of all adult-related TTP is obstetric.<xref ref-type="bibr" rid="article-30096.r16">[16]</xref><xref ref-type="bibr" rid="article-30096.r17">[17]</xref>&#x000a0;Up to 25% of patients with congenital TTP (also known as Upshaw-Schulman syndrome), characterized by the congenital absence of ADAMTS-13 (A&#x000a0;disintegrin and metalloproteinase with a thrombospondin type 1 motif, member&#x000a0;13), present for the first time during the first pregnancy or immediately postpartum.<xref ref-type="bibr" rid="article-30096.r16">[16]</xref><xref ref-type="bibr" rid="article-30096.r18">[18]</xref></p></list-item><list-item><p>Atypical hemolytic-uremic syndrome (HUS): Atypical HUS is seen in up to 1 in 25000 pregnancies and presents with MAHA and renal failure, either at near-term or post-partum.<xref ref-type="bibr" rid="article-30096.r17">[17]</xref></p></list-item></list>
</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Disseminated Intravascular Coagulation (DIC): DIC occurs in up to 0.35% of all pregnancies.<xref ref-type="bibr" rid="article-30096.r19">[19]</xref> Although DIC can occur in any trimester, it most commonly occurs in the third trimester, either as a direct consequence of an obstetric complication (eg, PPH, amniotic fluid embolism) or secondary to other pregnancy-related complications (PEC/ HELLP/ AFLP, etc).<xref ref-type="bibr" rid="article-30096.r19">[19]</xref></p>
          </list-item>
          <list-item>
            <p>Hereditary thrombocytopenia is a rare cause of thrombocytopenia in pregnancy, commonly diagnosed in the first trimester, although it can present during any trimester.<xref ref-type="bibr" rid="article-30096.r4">[4]</xref><xref ref-type="bibr" rid="article-30096.r6">[6]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Others: Bone marrow failure, antiphospholipid antibody syndrome, PNH, autoimmune conditions, and type II VWD are amongst the rare causes of thrombocytopenia in pregnancy. Less than 1% of patients develop thrombocytopenia secondary to 'other' causes listed.<xref ref-type="bibr" rid="article-30096.r9">[9]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30096.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The pathophysiology of thrombocytopenia depends on its etiology. This section discusses the pathophysiology of the major causes of thrombocytopenia in pregnancy.</p>
        <list list-type="order">
          <list-item>
            <p>Gestational thrombocytopenia: The mechanism behind gestation thrombocytopenia remains anecdotal.<xref ref-type="bibr" rid="article-30096.r6">[6]</xref>&#x000a0;Dilution from expanded plasma volume, formation of autoantibody against platelets, pooling or consumption of platelets in the placenta, changes in the activity of von Willebrand factor and ADAMTS-13,&#x000a0;increased macrophage colony-stimulating factors from the placenta and inadequate response to thrombopoietin are some of the proposed as the mechanisms leading to gestational thrombocytopenia.<xref ref-type="bibr" rid="article-30096.r20">[20]</xref><xref ref-type="bibr" rid="article-30096.r21">[21]</xref><xref ref-type="bibr" rid="article-30096.r22">[22]</xref><xref ref-type="bibr" rid="article-30096.r23">[23]</xref><xref ref-type="bibr" rid="article-30096.r24">[24]</xref>&#x000a0;In theory, gestational thrombocytopenia is considered a continuum of the dilutional changes of pregnancy, where the affected women are simply producing platelets at the lower end of the normal spectrum. However, the fact that it recurs with subsequent pregnancies; tends to develop late in the pregnancy (with increasing gravidity of uterus and changes in placental blood flow) and resolves soon after parturition (which excludes autoimmunity); reflects a&#x000a0;mechanism at maternal physiology which is still not completely understood.<xref ref-type="bibr" rid="article-30096.r6">[6]</xref><xref ref-type="bibr" rid="article-30096.r4">[4]</xref><xref ref-type="bibr" rid="article-30096.r20">[20]</xref></p>
          </list-item>
          <list-item>
            <p>Immune thrombocytopenia (ITP): ITP is a heterogeneous disease that can either be diagnosed during pregnancy or may flare up during pregnancy.<xref ref-type="bibr" rid="article-30096.r10">[10]</xref><xref ref-type="bibr" rid="article-30096.r6">[6]</xref> Up to 60% of patients have an antibody-mediated disease, but in up to 40% of patients, the driver for ITP may be malfunctioning T-cells or antigen-presenting cells.<xref ref-type="bibr" rid="article-30096.r25">[25]</xref> ITP&#x000a0;can present in association with a systemic autoimmune disease like systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), scleroderma, anti-phospholipid antibody syndrome (APLS), etc, which can present as a combination of autoimmune-mediated and&#x000a0;TMA induced thrombocytopenia.<xref ref-type="bibr" rid="article-30096.r10">[10]</xref><xref ref-type="bibr" rid="article-30096.r6">[6]</xref></p>
          </list-item>
          <list-item>
            <p>Thrombotic microangiopathy (TMA) is an umbrella of disorders united by common clinical and pathological features.<xref ref-type="bibr" rid="article-30096.r26">[26]</xref> The clinical presentation includes microangiopathic hemolytic anemia (MAHA), thrombocytopenia, and organ injury.<xref ref-type="bibr" rid="article-30096.r26">[26]</xref><xref ref-type="bibr" rid="article-30096.r27">[27]</xref> On a microscopic level, all TMA&#x02019;s are defined by vascular damage that manifests as arteriolar and capillary thrombosis, which present with characteristic abnormalities in the endothelium and vessel wall.<xref ref-type="bibr" rid="article-30096.r26">[26]</xref>
<list list-type="bullet"><list-item><p>Pregnancy-related TMA occurs secondary to obstetric complications like PEC, HELLP, and AFLP.<xref ref-type="bibr" rid="article-30096.r4">[4]</xref><xref ref-type="bibr" rid="article-30096.r20">[20]</xref> The pathogenesis of thrombocytopenia in PEC remains unexplained. The belief is that a hypoxic placenta releases antiangiogenic factors that cause endothelial dysfunction, which leads to the clinical manifestations of PEC.</p></list-item><list-item><p>The non-pregnancy-related TMA occurs due to the absence/inhibition of ADAMTS-13 (leads to TTP) or a mutation in the function or expression of proteins controlling the alternative pathway C3 convertase (leads to atypical HUS).<xref ref-type="bibr" rid="article-30096.r4">[4]</xref><xref ref-type="bibr" rid="article-30096.r26">[26]</xref></p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Disseminated Intravascular Coagulation (DIC): DIC denotes an imbalance between activated procoagulant pathways and impairment of the internal anticoagulant pathways and fibrinolytic systems.<xref ref-type="bibr" rid="article-30096.r28">[28]</xref> This imbalance in the coagulation system leads to platelet activation and consumption, along with fibrin deposition.<xref ref-type="bibr" rid="article-30096.r28">[28]</xref> It can occur either with a complication of the process of delivery (post-partum hemorrhage (PPH), uterine atony, vaginal lacerations, abruptio placentae, retained dead fetus) or in association with other complications of pregnancy like HELLP, AFLP, or other causes of TMA.<xref ref-type="bibr" rid="article-30096.r19">[19]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30096.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>A thorough history and physical exam help establish the etiology behind the low platelet count in any patient with thrombocytopenia.<xref ref-type="bibr" rid="article-30096.r2">[2]</xref> Usually, the signs and symptoms of thrombocytopenia do not occur unless the platelet count drops to a very low level or the patient presents with symptoms of the underlying disorder. A temporal profile of thrombocytopenia or its bleeding manifestations (acute, chronic, or relapsing-remitting) does not help determine the etiology of thrombocytopenia but helps determine the clinical phenotype.<xref ref-type="bibr" rid="article-30096.r2">[2]</xref> The past medical history of other diseases, such as existing autoimmune disorders (systemic lupus erythematosus, rheumatoid arthritis, etc), infections (rickettsiosis, malaria, etc), malignancies, and transplant recipients, is essential to establish the diagnosis.<xref ref-type="bibr" rid="article-30096.r2">[2]</xref> Likewise, a history of medications (quinine, antibiotics, heparin, etc), recent vaccinations, travel history, dietary practices, and high-risk behaviors (sexual practices, illicit drug use, smoking, alcohol consumption) also helps in guiding the evaluation of thrombocytopenia.<xref ref-type="bibr" rid="article-30096.r2">[2]</xref>&#x000a0;A thorough family history is vital in delineating congenital thrombocytopenia, which can present for the first time well into adulthood.<xref ref-type="bibr" rid="article-30096.r2">[2]</xref><xref ref-type="bibr" rid="article-30096.r7">[7]</xref></p>
        <p>A physical exam provides clues to determining the etiology of thrombocytopenia. Patients with gestational thrombocytopenia are often healthy, asymptomatic women who are found to have low platelets on lab investigations.<xref ref-type="bibr" rid="article-30096.r6">[6]</xref><xref ref-type="bibr" rid="article-30096.r5">[5]</xref><xref ref-type="bibr" rid="article-30096.r4">[4]</xref> On the contrary, a pregnant woman with TMA is usually a gravely ill patient, often presenting to the emergency room or being admitted to high-risk obstetric units. Patients with low platelet count usually present with mucocutaneous bleeding. However, joint bleed or severe bleeding should prompt a workup toward severe coagulopathies like DIC. Physical exam should also evaluate for hepatomegaly or splenomegaly (cirrhosis, lymphoproliferative disorders, etc), skeletal deformities (like absent radius, humeral abnormality, and sometimes phocomelia seen in thrombocytopenia absent radii syndrome) and skin exam (like petechiae or purpura seen commonly with ITP, or, eczema seen in Wiskott-Aldrich Syndrome).<xref ref-type="bibr" rid="article-30096.r7">[7]</xref><xref ref-type="bibr" rid="article-30096.r29">[29]</xref></p>
        <p>Specific history and physical exam clues can point a clinician toward an underlying etiology.</p>
        <list list-type="bullet">
          <list-item>
            <p>Gestational thrombocytopenia: It is diagnosed based on the following criteria.<xref ref-type="bibr" rid="article-30096.r6">[6]</xref><xref ref-type="bibr" rid="article-30096.r5">[5]</xref>
<list list-type="bullet"><list-item><p>onset in the mid-second to the third trimester</p></list-item><list-item><p>no symptoms in the mother and no history of bleeding</p></list-item><list-item><p>no effect on the outcome of the pregnancy</p></list-item><list-item><p>no thrombocytopenia in the neonate</p></list-item><list-item><p>self-limited course and resolution in 4 to 8 weeks</p></list-item><list-item><p>A tendency to recur with the same degree in subsequent pregnancies</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Pre-eclampsia: Patients present with severe hypertension after 20 weeks of gestation (defined as systolic pressure more than 160mmHg and diastolic pressure more than 110 mmHg on two separate occasions, at least 4 hours apart) or with severe persistent right upper quadrant epigastric pain which is unresponsive to medications. Eclampsia can present as a sequel to pre-eclampsia with seizures.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>HELLP syndrome: It correlates with generalized edema in more than 50% of patients who demonstrate hepatic and renal insufficiency in labs.<xref ref-type="bibr" rid="article-30096.r4">[4]</xref><xref ref-type="bibr" rid="article-30096.r5">[5]</xref></p>
          </list-item>
          <list-item>
            <p>AFLP: Clinically, it is quite challenging to distinguish between AFLP and HELLP syndrome. However, encephalopathy, hypoglycemia, and severe coagulopathy, along with TMA-like hemolysis, are more frequently present in patients with AFLP.<xref ref-type="bibr" rid="article-30096.r4">[4]</xref><xref ref-type="bibr" rid="article-30096.r5">[5]</xref></p>
          </list-item>
          <list-item>
            <p>PNH: Patients usually present with hemolytic anemia, pancytopenia, and thrombosis; however, the characteristic finding of hemoglobinuria is rarely seen.<xref ref-type="bibr" rid="article-30096.r30">[30]</xref>&#x000a0;Although thrombosis is a rare presenting feature, it usually occurs in atypical sites like the portal or cerebral veins.<xref ref-type="bibr" rid="article-30096.r30">[30]</xref></p>
          </list-item>
          <list-item>
            <p>HIT: A history of recent exposure to heparin is quintessential to the diagnosis of HIT. Thrombocytopenia usually develops within 5 to 10 days of exposure to heparin but can occur sooner if the previous exposure is relatively recent.&#x000a0;Skin necrosis or venous thromboembolism should prompt a workup towards HIT.&#x000a0;The clinical 4-T score also aids in the diagnosis of HIT.<xref ref-type="bibr" rid="article-30096.r31">[31]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30096.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Laboratory evaluation of thrombocytopenia starts with a review of peripheral smear. Pseudothrombocytopenia, defined as the clumping of platelets on peripheral smears, can happen in up to 1% of all pregnancies.<xref ref-type="bibr" rid="article-30096.r6">[6]</xref> This 'fictitious' thrombocytopenia occurs due to the collection of blood in ethylenediaminetetraacetic acid (EDTA) anticoagulated tubes. The EDTA-dependent platelet auto-antibodies lead to artifactual clumping on the peripheral smear. It can be corrected by collecting the blood in a heparin tube and then manually counting the peripheral smear.<xref ref-type="bibr" rid="article-30096.r2">[2]</xref> A review of a peripheral blood smear helps to determine the morphology of all three cell lines and the detection of red cell fragments (schistocytes) and atypical white cells like myeloblasts; this is particularly important in a critically ill pregnant patient with thrombocytopenia, where a review of peripheral smear must be done to look for schistocytes and rule out TMA.<xref ref-type="bibr" rid="article-30096.r4">[4]</xref><xref ref-type="bibr" rid="article-30096.r5">[5]</xref></p>
        <p>A complete blood count with differential helps realize the degree of thrombocytopenia and provides a clue about its etiology.<xref ref-type="bibr" rid="article-30096.r6">[6]</xref><xref ref-type="bibr" rid="article-30096.r5">[5]</xref><xref ref-type="bibr" rid="article-30096.r2">[2]</xref>&#x000a0;Evaluating thrombocytopenia in pregnancy starts by differentiating between isolated thrombocytopenia and thrombocytopenia, which occurs along with changes in red and white cell lines.</p>
        <list list-type="order">
          <list-item>
            <p>Thrombocytopenia, along with changes in other cell lines
<list list-type="bullet"><list-item><p>Thrombocytopenia and hemolytic anemia: TMA should be the first consideration in a pregnant woman presenting with anemia and thrombocytopenia.
<list list-type="bullet"><list-item><p>Hemolysis labs include lactate dehydrogenase, haptoglobin levels, total and direct bilirubin, and reticulocyte count, and the clinician should obtain an index in patients suspected of hemolytic anemia.<xref ref-type="bibr" rid="article-30096.r2">[2]</xref><xref ref-type="bibr" rid="article-30096.r5">[5]</xref></p></list-item><list-item><p>The diagnosis of TMA usually involves the triad of thrombocytopenia, hemolysis, and renal failure/injury.<xref ref-type="bibr" rid="article-30096.r32">[32]</xref><xref ref-type="bibr" rid="article-30096.r33">[33]</xref> The lab evaluation for pregnancy-related TMA and non-pregnancy-related TMA is similar; however, certain tests are needed to differentiate between PEC/HELLP, TTP, and atypical HUS.<xref ref-type="bibr" rid="article-30096.r33">[33]</xref>&#x000a0;Shiga-toxin must be tested in patients suspected of TMA to rule out typical HUS.<xref ref-type="bibr" rid="article-30096.r33">[33]</xref></p></list-item><list-item><p>Specific tests to rule out TTP include testing for ADAMTS-13. A level of ADAMTS-13 above 5 to 10% usually rules out TTP.<xref ref-type="bibr" rid="article-30096.r32">[32]</xref><xref ref-type="bibr" rid="article-30096.r33">[33]</xref></p></list-item><list-item><p>In patients suspected of atypical HUS, a genetic test must be pursued to identify mutations that prevent the expression or function of proteins involved in regulating the alternate C3 pathway.<xref ref-type="bibr" rid="article-30096.r33">[33]</xref></p></list-item></list>
</p></list-item><list-item><p>Thrombocytopenia associated with bleeding: A coagulation panel should always be done to identify any coagulopathy that may complicate thrombocytopenia with bleeding. As mentioned above, DIC can be associated with TMA or secondary to obstetric causes.<xref ref-type="bibr" rid="article-30096.r19">[19]</xref> There is no single test to identify DIC. Still, a score developed by the International Society of Thrombosis and Hemostasis (ISTH) helps predict DIC with a sensitivity of 93% and a specificity of 98%.&#x000a0;The components of the ISTH score include fibrinogen level, partial thromboplastin time, platelet count, and fibrin markers (D-dimer is a reasonable marker).<xref ref-type="bibr" rid="article-30096.r28">[28]</xref></p></list-item><list-item><p>Paroxysmal nocturnal hemoglobinuria (PNH):&#x000a0;The diagnosis of PNH is via flow cytometric&#x000a0;analysis of glycosyl-phosphatidylinositol-anchored&#x000a0;proteins (GPI-AP) along with a decreased expression of both CD55 and CD59. CD55 and CD59 are still tested to&#x000a0;exclude rare, inherited deficiency of single GPI-AP.<xref ref-type="bibr" rid="article-30096.r30">[30]</xref></p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Isolated thrombocytopenia:
<list list-type="bullet"><list-item><p>Immune thrombocytopenia: ITP usually presents as isolated thrombocytopenia with petechiae or bleeding manifestations.<xref ref-type="bibr" rid="article-30096.r6">[6]</xref><xref ref-type="bibr" rid="article-30096.r5">[5]</xref> The workup for ITP follows the American Society of Hematology guidelines (2011) and the International Working Group (2010). The mandatory tests include a lab evaluation for hepatitis B and C, human immunodeficiency virus, quantitative immunoglobulins, direct antiglobulin test, and blood group (Rh). Tests that can be of potential utility in such patients include antiphospholipid antibodies, anti-nuclear antibodies, anti-thyroid antibodies, thyroid function tests, and viral studies for cytomegalovirus. <italic toggle="yes">Helicobacter Pylori</italic> testing should take place in areas with high prevalence.<xref ref-type="bibr" rid="article-30096.r34">[34]</xref><xref ref-type="bibr" rid="article-30096.r35">[35]</xref></p></list-item><list-item><p>Heparin-induced thrombocytopenia (HIT): Although rare, HIT can cause thrombocytopenia in pregnancy.<xref ref-type="bibr" rid="article-30096.r8">[8]</xref> HIT is diagnosed based on clinical and pathological features. The 4T score helps determine the clinical probability of HIT and the anti-platelet Factor-4 (PF-4)/heparin antibodies to help make a pathological diagnosis. The PF-4-dependent enzyme immunoassays (EIA) have a high sensitivity and specificity for HIT antibodies, especially if the cut-off for optical density is raised (in comparison to the serotonin-release assay (SRA). However, all positive EIA should be tested with washed platelet assays (like carbon-14-SRA) to confirm the diagnosis.<xref ref-type="bibr" rid="article-30096.r31">[31]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <p>Gestational thrombocytopenia is a diagnosis of exclusion based on a thorough history and physical exam and ruling out conflicting diagnoses with lab support. With sufficient exclusion of other etiologies, no further laboratory evaluation is needed to confirm a gestational thrombocytopenia diagnosis.<xref ref-type="bibr" rid="article-30096.r6">[6]</xref><xref ref-type="bibr" rid="article-30096.r5">[5]</xref> Rarely does the platelet count drop below 70 x&#x000a0;10<sup>9</sup>/L in patients with gestational thrombocytopenia. If the platelet count goes below&#x000a0;70 x 10<sup>9</sup>/L, then the patient should be evaluated for a secondary cause like ITP. <xref ref-type="bibr" rid="article-30096.r4">[4]</xref><xref ref-type="bibr" rid="article-30096.r5">[5]</xref></p>
      </sec>
      <sec id="article-30096.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>In pregnancy, thrombocytopenia usually does not lead to an increased risk of bleeding.&#x000a0;Even in patients with ITP, where thrombocytopenia is often quite severe, the risk of bleeding remains low.&#x000a0;The obstetric indication decides the mode of delivery.&#x000a0;Vaginal delivery is preferable from a hematologic standpoint due to the lower risk of bleeding; however, this is not a deciding factor.&#x000a0;Administration of neuraxial anesthesia (epidural anesthesia) is a challenge. The American College of Obstetrics and Gynecology recommends a platelet count of 80 x 10<sup>9</sup>/L (level C recommendation) as the goal of administering epidural anesthesia.&#x000a0;The platelet goal for delivery is more than 50 x 10<sup>9</sup>/L, especially if planning a cesarean section.<xref ref-type="bibr" rid="article-30096.r5">[5]</xref><xref ref-type="bibr" rid="article-30096.r6">[6]</xref> Here, we briefly discuss the management of pregnant patients with thrombocytopenia according to the etiology of the disease.</p>
        <list list-type="order">
          <list-item>
            <p>Gestational Thrombocytopenia: The platelet count rarely&#x000a0;goes below 70 x 10<sup>9</sup>/L in patients with gestational thrombocytopenia. No intervention is required in such patients as the condition resolves spontaneously 4 to 8 weeks after delivery. In patients whose platelet counts drop below 70 x 10<sup>9</sup>/L, a component of ITP merits consideration. The use of steroids and intravenous immunoglobulins&#x000a0;does not&#x000a0;benefit patients with gestational thrombocytopenia. However, it may help those who have&#x000a0;ITP superimposed on gestational thrombocytopenia. The neonatal outcomes are excellent, and neonates of mothers with gestational thrombocytopenia never develop thrombocytopenia.<xref ref-type="bibr" rid="article-30096.r5">[5]</xref><xref ref-type="bibr" rid="article-30096.r6">[6]</xref><xref ref-type="bibr" rid="article-30096.r4">[4]</xref></p>
          </list-item>
          <list-item>
            <p>Immune thrombocytopenia (ITP): ITP is a complex and heterogeneous disease. Although many treatment options exist for adult patients with ITP, pregnancy offers a unique challenge in terms of minimizing the fetal-maternal risk. Usually, an intervention is unnecessary unless the platelet counts drop below 20 to 30 x 10<sup>9</sup>/L in the first two trimesters or if thrombocytopenia is complicated with bleeding, regardless of the platelet count. Treatment in the third trimester depends on the mode of delivery and candidacy for epidural anesthesia.<xref ref-type="bibr" rid="article-30096.r6">[6]</xref> Corticosteroids are usually the first line of treatment in pregnant patients, with a response time of 3 to 7 days.<xref ref-type="bibr" rid="article-30096.r34">[34]</xref>&#x000a0;They are associated with minimal risk of fetal orofacial cleft palate if started in the first trimester. They may lead to maternal diabetes, weight gain, and hypertension if started in the third trimester.<xref ref-type="bibr" rid="article-30096.r36">[36]</xref><xref ref-type="bibr" rid="article-30096.r6">[6]</xref><xref ref-type="bibr" rid="article-30096.r5">[5]</xref> A single dose of intravenous immunoglobulins (IVIG) at 1000mg/kg can rapidly raise platelets within 24 hours.&#x000a0;However, the response lasts only for 2 to 3 weeks.&#x000a0;One more dose can be repeated either alone or in combination with steroids if unable to achieve the desired response.<xref ref-type="bibr" rid="article-30096.r34">[34]</xref> It is associated with a small risk of renal tubular acidosis and thrombosis.<xref ref-type="bibr" rid="article-30096.r34">[34]</xref>&#x000a0;The FDA has classified anti-D, rituximab, and thrombopoietin receptor agonists as category C.<xref ref-type="bibr" rid="article-30096.r5">[5]</xref>&#x000a0;Rituximab has been used safely during pregnancy, with minimal complications to the mother. There are reports of transient neonatal B-cell lymphopenia with the use of rituximab, which resolves by six months of age.<xref ref-type="bibr" rid="article-30096.r37">[37]</xref>&#x000a0;Splenectomy can be done safely via a laparoscopic approach in the second and third trimester of pregnancy.&#x000a0;However, it is rarely pursued in the modern era and is reserved for patients refractory to medical management.<xref ref-type="bibr" rid="article-30096.r5">[5]</xref><xref ref-type="bibr" rid="article-30096.r34">[34]</xref> Other&#x000a0;medical options include azathioprine and cyclosporine. The use of chemotherapeutic agents like cyclophosphamide, vincristine, etc, is usually discouraged in pregnant patients.<xref ref-type="bibr" rid="article-30096.r38">[38]</xref> Mycophenolate mofetil is contraindicated in pregnancy due to teratogenic effects on the fetus.<xref ref-type="bibr" rid="article-30096.r38">[38]</xref></p>
          </list-item>
          <list-item>
            <p>Thrombotic Microangiopathy: The management of TMA in pregnancy focuses on the antecedent cause. The thrombocytopenia is a consequence of the TMA and improves with the resolution of the underlying condition.&#x000a0;It is critical to differentiate between pregnancy-specific TMA (PEC/HELLP/AFLP) and non-pregnancy-specific TMA, as the management of the two conditions is very different.&#x000a0;
<list list-type="bullet"><list-item><p>PEC/HELLP syndrome/AFLP: The goal of treatment is the delivery of the fetus, with supportive care provided for the management of the underlying condition.<xref ref-type="bibr" rid="article-30096.r38">[38]</xref></p></list-item><list-item><p>TTP: prompt initiation of plasma exchange helps remove the inhibitor to ADAMTS-13 and supply the patients with fresh plasma to restore the&#x000a0;function of ADAMTS-13 and resolve hemolysis.<xref ref-type="bibr" rid="article-30096.r32">[32]</xref> Eventually, anti-inhibitor therapy is initiated to reduce the inhibitor activity. Up to 25% of patients presenting with TTP in adulthood have a congenital absence of ADAMTS-13 (Upshaw-Schulman syndrome).<xref ref-type="bibr" rid="article-30096.r16">[16]</xref> In such patients, anti-inhibitor therapy has no role. Such patients should receive periodic infusions of plasma.<xref ref-type="bibr" rid="article-30096.r39">[39]</xref> Trials&#x000a0;regarding a recombinant ADAMTS-13 are underway to circumvent the need for plasma infusions.<xref ref-type="bibr" rid="article-30096.r39">[39]</xref>&#x000a0;Caplacizumab (CABLIVI) was approved by the FDA in 2019 for treating adult patients with acquired TTP in combination with plasma exchange and immunosuppressive therapy. A von Willebrand factor (vWF)-directed antibody fragment targets the A1-domain of vWF and inhibits the interaction between vWF and platelets, thereby reducing both vWF-mediated platelet adhesion and platelet consumption.&#x000a0;Its safety in pregnancy has not been established and increases the risk of hemorrhage in both mother and fetus.<xref ref-type="bibr" rid="article-30096.r40">[40]</xref>&#x000a0;</p></list-item><list-item><p>Atypical HUS: Plasma exchange is not useful in patients with atypical HUS.&#x000a0;The FDA has approved eculizumab for patients diagnosed with atypical HUS.<xref ref-type="bibr" rid="article-30096.r41">[41]</xref><xref ref-type="bibr" rid="article-30096.r42">[42]</xref> Despite being labeled category C by the FDA, several reports have shown that eculizumab can be safely administered during pregnancy.<xref ref-type="bibr" rid="article-30096.r43">[43]</xref><xref ref-type="bibr" rid="article-30096.r44">[44]</xref></p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>PNH: Eculizumab is a humanized monoclonal IgG antibody that prevents cleavage of C5 into C5a and C5b, eventually blocking the formation of membrane attack complexes. It leads to a reduction in complement-mediated hemolysis and improvement in platelet count.<xref ref-type="bibr" rid="article-30096.r42">[42]</xref> As stated above, several reports demonstrate the safety of eculizumab.<xref ref-type="bibr" rid="article-30096.r44">[44]</xref><xref ref-type="bibr" rid="article-30096.r43">[43]</xref></p>
          </list-item>
          <list-item>
            <p>Disseminated intravascular coagulation: DIC is a consumptive coagulopathy whose primary goal is to treat the underlying cause. However, patients with severe DIC may require supportive measures. Patients in DIC present either with a bleeding phenotype or overt thromboembolism. A bleeding patient's platelet transfusion goals are 30 to 50 x 10<sup>9</sup>/L.<xref ref-type="bibr" rid="article-30096.r28">[28]</xref> Plasma/ cryoprecipitate is given to prolong prothrombin time by less than 3 seconds and to prolong fibrinogen above 1.5 gm/L.<xref ref-type="bibr" rid="article-30096.r28">[28]</xref> In a patient with overt thromboembolism, the clinician should initiate full-dose anticoagulation.<xref ref-type="bibr" rid="article-30096.r19">[19]</xref><xref ref-type="bibr" rid="article-30096.r28">[28]</xref></p>
          </list-item>
          <list-item>
            <p>Heparin-induced thrombocytopenia: HIT rarely complicates pregnancy unless the patient receives heparin products. After confirming the diagnosis via a platelet activation assay (serotonin release assay is the most commonly used assay), patients should not receive heparin products anymore. Direct thrombin inhibitors (argatroban and bivalirudin) serve to manage such patients immediately.<xref ref-type="bibr" rid="article-30096.r31">[31]</xref> For the follow-up anticoagulation, fondaparinux is an option for anticoagulation in pregnant patients.<xref ref-type="bibr" rid="article-30096.r45">[45]</xref><xref ref-type="bibr" rid="article-30096.r46">[46]</xref><xref ref-type="bibr" rid="article-30096.r47">[47]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30096.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The workup of thrombocytopenia in pregnancy focuses on establishing the etiology of low platelets. A list of potential diagnoses is listed above.&#x000a0;</p>
      </sec>
      <sec id="article-30096.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis depends on the underlying etiology of thrombocytopenia. While thrombocytopenia does not lead to complications in pregnancy, the etiology behind the thrombocytopenia can pose&#x000a0;significant challenges. The mode of delivery is chosen based on the obstetric indication.<xref ref-type="bibr" rid="article-30096.r4">[4]</xref><xref ref-type="bibr" rid="article-30096.r5">[5]</xref></p>
        <list list-type="order">
          <list-item>
            <p>Gestational thrombocytopenia: It is a self-limiting condition that usually resolves within 4 to 8 weeks of delivery of the fetus. Although there is a high risk of recurrence with subsequent pregnancies, it is often a benign condition that seldom causes any complications in the mother.<xref ref-type="bibr" rid="article-30096.r4">[4]</xref><xref ref-type="bibr" rid="article-30096.r5">[5]</xref></p>
          </list-item>
          <list-item>
            <p>Immune thrombocytopenia: ITP can lead to significant bleeding issues in the mother. ITP in the mother can also affect the neonate and lead to neonatal thrombocytopenia. Despite low platelets, the risk of bleeding is quite low in the mother. In neonates who have thrombocytopenia secondary to maternal ITP, catastrophic bleeding events (like intracranial hemorrhage) occur in less than 1% of patients.<xref ref-type="bibr" rid="article-30096.r4">[4]</xref><xref ref-type="bibr" rid="article-30096.r5">[5]</xref></p>
          </list-item>
          <list-item>
            <p>TMA: Both pregnancy-related TMA (PEC/HELLP/AFLP) and TMA not specific to pregnancy (TTP/ATypical HUS) are associated with high rates of maternal and neonatal morbidity and mortality. Thrombocytopenia related to these conditions seldom poses any issues in the mother or the neonate. The goal of treatment is the delivery of the baby.<xref ref-type="bibr" rid="article-30096.r4">[4]</xref><xref ref-type="bibr" rid="article-30096.r5">[5]</xref>&#x000a0;Platelet count recovery may lag behind the delivery of the fetus but eventually resolves once the underlying condition improves.<xref ref-type="bibr" rid="article-30096.r4">[4]</xref><xref ref-type="bibr" rid="article-30096.r5">[5]</xref></p>
          </list-item>
          <list-item>
            <p>Clinicians should manage other causes of thrombocytopenia (bone marrow failure syndrome, PNH, etc) according to their primary etiology; the prognosis depends on the underlying etiology.</p>
          </list-item>
        </list>
        <p>Neonatal outcome in women with thrombocytopenia:</p>
        <list list-type="order">
          <list-item>
            <p>The neonatal outcome is excellent in neonates born to mothers with gestational thrombocytopenia. They never develop thrombocytopenia or are at risk of bleeding.</p>
          </list-item>
          <list-item>
            <p>Neonates born to mothers with ITP may develop transient thrombocytopenia. Although&#x000a0;the passive transfer of antibodies from the mother causes transient thrombocytopenia in the neonate, the most popular theory behind neonates developing thrombocytopenia has not been entirely proven. The nadir of platelets appears within 24 to 48 hours. Reports of intracranial hemorrhage appear in less than 1% of neonates who develop thrombocytopenia secondary to maternal ITP.<xref ref-type="bibr" rid="article-30096.r4">[4]</xref><xref ref-type="bibr" rid="article-30096.r5">[5]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30096.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Thrombocytopenia in pregnancy seldom leads to bleeding in pregnancy, even with very low platelet counts seen in ITP.<xref ref-type="bibr" rid="article-30096.r11">[11]</xref>&#x000a0;The complications are secondary to the underlying etiology and are discussed in the management section.</p>
      </sec>
      <sec id="article-30096.s12" sec-type="Consultations">
        <title>Consultations</title>
        <p>A high-risk obstetric clinic should follow any patient with thrombocytopenia in pregnancy. A hematology consult is needed if the platelet count drops below 70 x 10<sup>9</sup>/L or if a pregnant woman with thrombocytopenia develops bleeding. It is critical to involve a hematologist in the management of TMA that is not specific to pregnancy (TTP and atypical HUS) and other rare causes of thrombocytopenia.&#x000a0;</p>
      </sec>
      <sec id="article-30096.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Though thrombocytopenia in pregnancy is benign in most patients, it should be investigated thoroughly, especially if the platelet count drops below 70 x 10<sup>9</sup>/L. In the case of gestational thrombocytopenia, patients require reassurance about the benign nature of the diagnosis. Appropriate treatment for the underlying etiology should start as soon as possible, and the patients and family members should receive appropriately targeted education. Patients should be followed for platelet counts every 2 to 4 weeks to observe a trend in their platelet counts and every&#x000a0;2 weeks in the near term. Patients and family members should understand that the mode of delivery (vaginal or cesarean section) is decided based on obstetric indication and not the platelet count. In addition to this, patients should also know that platelet transfusions are not routine therapy for thrombocytopenia in pregnancy.&#x000a0;The delivery is usually uncomplicated if their platelet count is over 50 x 10<sup>9</sup>/L. However, a goal of more than 80 x 10<sup>9</sup>/L is appropriate for administering epidural anesthesia. An expert hematologist should be involved in the care of pregnant women with thrombocytopenia if the platelet count drops below 70 x 10<sup>9</sup>/L or if bleeding develops.<xref ref-type="bibr" rid="article-30096.r4">[4]</xref><xref ref-type="bibr" rid="article-30096.r5">[5]</xref></p>
      </sec>
      <sec id="article-30096.s14" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Thrombocytopenia in pregnancy is a benign condition in the majority of patients. However, it may be associated with more severe etiologies in a few patients. A few noteworthy points are listed here.</p>
        <list list-type="bullet">
          <list-item>
            <p>Less than 1% of pregnant patients with thrombocytopenia have a platelet count of less than 100 x 10<sup>9</sup>/L.</p>
          </list-item>
          <list-item>
            <p>A thorough history and complete physical are the initial steps in evaluating thrombocytopenia in pregnancy.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>A peripheral smear review is the first step in the lab evaluation of thrombocytopenia. It helps in ruling out pseudo-thrombocytopenia and schistocytes.</p>
          </list-item>
          <list-item>
            <p>Gestational thrombocytopenia, which is the most common cause of&#x000a0;thrombocytopenia in pregnancy, is a diagnosis of exclusion.</p>
          </list-item>
          <list-item>
            <p>Despite being the most common cause of thrombocytopenia in pregnancy, gestational thrombocytopenia does not require any intervention as it resolves spontaneously.</p>
          </list-item>
          <list-item>
            <p>ITP is the most frequent cause of thrombocytopenia in the first trimester of pregnancy. However, it is also a diagnosis of exclusion.</p>
          </list-item>
          <list-item>
            <p>Corticosteroids and IVIG are the first-line treatment for ITP in pregnancy.</p>
          </list-item>
          <list-item>
            <p>Rituximab is safe in pregnancy for the treatment of ITP, although it may cause transient B-cell lymphopenia in the neonate, which resolves spontaneously.</p>
          </list-item>
          <list-item>
            <p>Pregnancy-related TMA management is by the delivery of the fetus. Thrombocytopenia and other&#x000a0;abnormalities may take longer to recover after the delivery of the fetus.</p>
          </list-item>
          <list-item>
            <p>TTP is rare during pregnancy, but 10 to 30% of all patients with TTP are obstetric. Up to 25% of TTP in pregnancy is due to a congenital lack of ADAMTS-13 (Upshaw-Schulman syndrome).</p>
          </list-item>
          <list-item>
            <p>Eculizumab is designated category C by the FDA, but several reports show that it is safe for the management of atypical HUS and PNH in pregnancy.</p>
          </list-item>
        </list>
        <p>Important points to remember for both physicians and patients:</p>
        <list list-type="bullet">
          <list-item>
            <p>The mode of delivery depends on the obstetric indication rather than the platelet count.</p>
          </list-item>
          <list-item>
            <p>A platelet count of more than 50 x 10<sup>9</sup>/L is safe for delivery.</p>
          </list-item>
          <list-item>
            <p>The goal of platelets for administering neuraxial anesthesia is at 80 x 10<sup>9</sup>/L.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>If the platelet count drops below 70 x 10<sup>9</sup>/L, a secondary cause, like ITP, should be considered in a patient with gestational thrombocytopenia.</p>
          </list-item>
          <list-item>
            <p>Platelet transfusions are not required for low platelet counts unless the patient is bleeding.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>The neonatal outcome is excellent in&#x000a0;neonates born to mothers with gestational thrombocytopenia.</p>
          </list-item>
          <list-item>
            <p>Transient thrombocytopenia can present in neonates born to mothers with ITP. In less than 1% of neonates, it can lead to intracranial hemorrhage. A pediatrician consult is necessary for such a scenario.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Maternal and neonatal morbidity and mortality are high in patients with TMA. The primary goal of treatment is the delivery of the fetus.&#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30096.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Thrombocytopenia is the second most prevalent hematological abnormality in pregnancy. Less than 1% of pregnant women with thrombocytopenia during pregnancy would have a platelet count of less than 100 x 10<sup>9</sup>/L. Gestational thrombocytopenia is the most frequent cause of thrombocytopenia in pregnancy and requires vigilant monitoring in the clinic and reassurance to the patient. There is a need for communication between the obstetrics team, hematologists, pediatricians, and nurses involved in managing pregnant women with thrombocytopenia. Most evidence in managing patients with gestational thrombocytopenia and ITP comes from retrospective observational studies or Cohort-Control studies.<xref ref-type="bibr" rid="article-30096.r4">[4]</xref><xref ref-type="bibr" rid="article-30096.r5">[5]</xref> The rarer causes of thrombocytopenia in pregnancy are investigated based on the presenting signs and symptoms.</p>
        <p>Pregnancy-related thrombocytopenia requires an interprofessional approach to care. Clinician involvement was discussed above, but they do not operate alone. Specialty-trained nursing staff (maternal-newborn and neonatal)&#x000a0;are on hand to assist with delivery, medication administration, and monitoring the mother and baby before and throughout the delivery process. The medications used in thrombocytopenia require pharmacist input, who verify dosing, check for interactions, and suggest therapeutic alternatives when necessary. The clinicians may be running the show, but they need their supporting actors on the interprofessional healthcare team to effectively bring both the mother and newborn to a successful outcome.</p>
      </sec>
      <sec id="article-30096.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30096&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30096">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/blood-disorders/thrombocytopenia-in-pregnancy/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=30096">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/30096/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=30096">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-30096.s17">
        <title>References</title>
        <ref id="article-30096.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gernsheimer</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>James</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Stasi</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>How I treat thrombocytopenia in pregnancy.</article-title>
            <source>Blood</source>
            <year>2013</year>
            <month>Jan</month>
            <day>03</day>
            <volume>121</volume>
            <issue>1</issue>
            <fpage>38</fpage>
            <page-range>38-47</page-range>
            <pub-id pub-id-type="pmid">23149846</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30096.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stasi</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>How to approach thrombocytopenia.</article-title>
            <source>Hematology Am Soc Hematol Educ Program</source>
            <year>2012</year>
            <volume>2012</volume>
            <fpage>191</fpage>
            <page-range>191-7</page-range>
            <pub-id pub-id-type="pmid">23233580</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30096.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rodeghiero</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Stasi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gernsheimer</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Michel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Provan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Arnold</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Bussel</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Cines</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Chong</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Godeau</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lechner</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mazzucconi</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>McMillan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sanz</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Imbach</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Blanchette</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>K&#x000fc;hne</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ruggeri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>George</surname>
                <given-names>JN</given-names>
              </name>
            </person-group>
            <article-title>Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group.</article-title>
            <source>Blood</source>
            <year>2009</year>
            <month>Mar</month>
            <day>12</day>
            <volume>113</volume>
            <issue>11</issue>
            <fpage>2386</fpage>
            <page-range>2386-93</page-range>
            <pub-id pub-id-type="pmid">19005182</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30096.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cines</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>LD</given-names>
              </name>
            </person-group>
            <article-title>Thrombocytopenia in pregnancy.</article-title>
            <source>Blood</source>
            <year>2017</year>
            <month>Nov</month>
            <day>23</day>
            <volume>130</volume>
            <issue>21</issue>
            <fpage>2271</fpage>
            <page-range>2271-2277</page-range>
            <pub-id pub-id-type="pmid">28637667</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30096.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Myers</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and management of maternal thrombocytopenia in pregnancy.</article-title>
            <source>Br J Haematol</source>
            <year>2012</year>
            <month>Jul</month>
            <volume>158</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-15</page-range>
            <pub-id pub-id-type="pmid">22551110</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30096.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fogerty</surname>
                <given-names>AE</given-names>
              </name>
            </person-group>
            <article-title>Thrombocytopenia in Pregnancy: Mechanisms and Management.</article-title>
            <source>Transfus Med Rev</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>32</volume>
            <issue>4</issue>
            <fpage>225</fpage>
            <page-range>225-229</page-range>
            <pub-id pub-id-type="pmid">30177431</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30096.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>D'Andrea</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Chetta</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Margaglione</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Inherited platelet disorders: thrombocytopenias and thrombocytopathies.</article-title>
            <source>Blood Transfus</source>
            <year>2009</year>
            <month>Oct</month>
            <volume>7</volume>
            <issue>4</issue>
            <fpage>278</fpage>
            <page-range>278-92</page-range>
            <pub-id pub-id-type="pmid">20011639</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30096.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chaudhary</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Nepal</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Khanal</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Pathak</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Giri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bhatt</surname>
                <given-names>VR</given-names>
              </name>
            </person-group>
            <article-title>Management and Outcome of Heparin-Induced Thrombocytopenia in Pregnancy: A Systematic Review.</article-title>
            <source>Cardiovasc Hematol Agents Med Chem</source>
            <year>2015</year>
            <volume>13</volume>
            <issue>2</issue>
            <fpage>92</fpage>
            <page-range>92-7</page-range>
            <pub-id pub-id-type="pmid">26695420</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30096.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Townsley</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Hematologic complications of pregnancy.</article-title>
            <source>Semin Hematol</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>50</volume>
            <issue>3</issue>
            <fpage>222</fpage>
            <page-range>222-31</page-range>
            <pub-id pub-id-type="pmid">23953339</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30096.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Piatek</surname>
                <given-names>CI</given-names>
              </name>
              <name>
                <surname>El-Hemaidi</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Feinstein</surname>
                <given-names>DI</given-names>
              </name>
              <name>
                <surname>Liebman</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Akhtari</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Management of immune-mediated cytopenias in pregnancy.</article-title>
            <source>Autoimmun Rev</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>14</volume>
            <issue>9</issue>
            <fpage>806</fpage>
            <page-range>806-11</page-range>
            <pub-id pub-id-type="pmid">25981747</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30096.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Webert</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Mittal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sigouin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Heddle</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Kelton</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>A retrospective 11-year analysis of obstetric patients with idiopathic thrombocytopenic purpura.</article-title>
            <source>Blood</source>
            <year>2003</year>
            <month>Dec</month>
            <day>15</day>
            <volume>102</volume>
            <issue>13</issue>
            <fpage>4306</fpage>
            <page-range>4306-11</page-range>
            <pub-id pub-id-type="pmid">12947011</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30096.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Duley</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>The global impact of pre-eclampsia and eclampsia.</article-title>
            <source>Semin Perinatol</source>
            <year>2009</year>
            <month>Jun</month>
            <volume>33</volume>
            <issue>3</issue>
            <fpage>130</fpage>
            <page-range>130-7</page-range>
            <pub-id pub-id-type="pmid">19464502</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30096.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abildgaard</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Heimdal</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Pathogenesis of the syndrome of hemolysis, elevated liver enzymes, and low platelet count (HELLP): a review.</article-title>
            <source>Eur J Obstet Gynecol Reprod Biol</source>
            <year>2013</year>
            <month>Feb</month>
            <volume>166</volume>
            <issue>2</issue>
            <fpage>117</fpage>
            <page-range>117-23</page-range>
            <pub-id pub-id-type="pmid">23107053</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30096.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nelson</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Yost</surname>
                <given-names>NP</given-names>
              </name>
              <name>
                <surname>Cunningham</surname>
                <given-names>FG</given-names>
              </name>
            </person-group>
            <article-title>Acute fatty liver of pregnancy: clinical outcomes and expected duration of recovery.</article-title>
            <source>Am J Obstet Gynecol</source>
            <year>2013</year>
            <month>Nov</month>
            <volume>209</volume>
            <issue>5</issue>
            <fpage>456.e1</fpage>
            <page-range>456.e1-7</page-range>
            <pub-id pub-id-type="pmid">23860212</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30096.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Allen</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>WR</given-names>
              </name>
              <name>
                <surname>Larson</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Rosedahl</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Yawn</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>McKeon</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hay</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>The Epidemiology of Liver Diseases Unique to Pregnancy in a US Community: A Population-Based Study.</article-title>
            <source>Clin Gastroenterol Hepatol</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>287</fpage>
            <page-range>287-94.e1-2</page-range>
            <pub-id pub-id-type="pmid">26305066</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30096.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moatti-Cohen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Garrec</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wolf</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Boisseau</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Galicier</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Azoulay</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Stepanian</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Delmas</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Rondeau</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bezieau</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Coppo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Veyradier</surname>
                <given-names>A</given-names>
              </name>
              <collab>French Reference Center for Thrombotic Microangiopathies</collab>
            </person-group>
            <article-title>Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura.</article-title>
            <source>Blood</source>
            <year>2012</year>
            <month>Jun</month>
            <day>14</day>
            <volume>119</volume>
            <issue>24</issue>
            <fpage>5888</fpage>
            <page-range>5888-97</page-range>
            <pub-id pub-id-type="pmid">22547583</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30096.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scully</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Thrombotic Thrombocytopenic Purpura and Atypical Hemolytic Uremic Syndrome Microangiopathy in Pregnancy.</article-title>
            <source>Semin Thromb Hemost</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>42</volume>
            <issue>7</issue>
            <fpage>774</fpage>
            <page-range>774-779</page-range>
            <pub-id pub-id-type="pmid">27648610</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30096.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scully</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Underwood</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Watson</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Langley</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Camilleri</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Creagh</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rayment</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mcdonald</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Roy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>McGuckin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ni Ainle</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Maclean</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lester</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Nash</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>O Brien</surname>
                <given-names>P</given-names>
              </name>
              <collab>collaborators of the UK TTP Registry</collab>
            </person-group>
            <article-title>Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes.</article-title>
            <source>Blood</source>
            <year>2014</year>
            <month>Jul</month>
            <day>10</day>
            <volume>124</volume>
            <issue>2</issue>
            <fpage>211</fpage>
            <page-range>211-9</page-range>
            <pub-id pub-id-type="pmid">24859360</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30096.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Erez</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Mastrolia</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Thachil</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Disseminated intravascular coagulation in pregnancy: insights in pathophysiology, diagnosis and management.</article-title>
            <source>Am J Obstet Gynecol</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>213</volume>
            <issue>4</issue>
            <fpage>452</fpage>
            <page-range>452-63</page-range>
            <pub-id pub-id-type="pmid">25840271</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30096.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McCrae</surname>
                <given-names>KR</given-names>
              </name>
            </person-group>
            <article-title>Thrombocytopenia in pregnancy: differential diagnosis, pathogenesis, and management.</article-title>
            <source>Blood Rev</source>
            <year>2003</year>
            <month>Mar</month>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>7</fpage>
            <page-range>7-14</page-range>
            <pub-id pub-id-type="pmid">12490206</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30096.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Freedman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Musclow</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Garvey</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Abbott</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Unexplained periparturient thrombocytopenia.</article-title>
            <source>Am J Hematol</source>
            <year>1986</year>
            <month>Apr</month>
            <volume>21</volume>
            <issue>4</issue>
            <fpage>397</fpage>
            <page-range>397-407</page-range>
            <pub-id pub-id-type="pmid">3953558</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30096.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lattuada</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rossi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Calzarossa</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Candolfi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mannucci</surname>
                <given-names>PM</given-names>
              </name>
            </person-group>
            <article-title>Mild to moderate reduction of a von Willebrand factor cleaving protease (ADAMTS-13) in pregnant women with HELLP microangiopathic syndrome.</article-title>
            <source>Haematologica</source>
            <year>2003</year>
            <month>Sep</month>
            <volume>88</volume>
            <issue>9</issue>
            <fpage>1029</fpage>
            <page-range>1029-34</page-range>
            <pub-id pub-id-type="pmid">12969811</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30096.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>S&#x000e1;nchez-Luceros</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Far&#x000ed;as</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Amaral</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Kempfer</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Votta</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Marchese</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Salvi&#x000fa;</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Woods</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>Meschengieser</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Lazzari</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>von Willebrand factor-cleaving protease (ADAMTS13) activity in normal non-pregnant women, pregnant and post-delivery women.</article-title>
            <source>Thromb Haemost</source>
            <year>2004</year>
            <month>Dec</month>
            <volume>92</volume>
            <issue>6</issue>
            <fpage>1320</fpage>
            <page-range>1320-6</page-range>
            <pub-id pub-id-type="pmid">15583740</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30096.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jing</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kong</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Qiu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Peng</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hou</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Thrombopoietin: a potential diagnostic indicator of immune thrombocytopenia in pregnancy.</article-title>
            <source>Oncotarget</source>
            <year>2016</year>
            <month>Feb</month>
            <day>16</day>
            <volume>7</volume>
            <issue>7</issue>
            <fpage>7489</fpage>
            <page-range>7489-96</page-range>
            <pub-id pub-id-type="pmid">26840092</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30096.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sullivan</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Ni</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Pathophysiology of immune thrombocytopenia.</article-title>
            <source>Curr Opin Hematol</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>25</volume>
            <issue>5</issue>
            <fpage>373</fpage>
            <page-range>373-381</page-range>
            <pub-id pub-id-type="pmid">30015642</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30096.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>George</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Nester</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Syndromes of thrombotic microangiopathy.</article-title>
            <source>N Engl J Med</source>
            <year>2014</year>
            <month>Nov</month>
            <day>06</day>
            <volume>371</volume>
            <issue>19</issue>
            <fpage>1847</fpage>
            <page-range>1847-8</page-range>
            <pub-id pub-id-type="pmid">25372103</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30096.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moake</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Thrombotic microangiopathies.</article-title>
            <source>N Engl J Med</source>
            <year>2002</year>
            <month>Aug</month>
            <day>22</day>
            <volume>347</volume>
            <issue>8</issue>
            <fpage>589</fpage>
            <page-range>589-600</page-range>
            <pub-id pub-id-type="pmid">12192020</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30096.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Levi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Scully</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>How I treat disseminated intravascular coagulation.</article-title>
            <source>Blood</source>
            <year>2018</year>
            <month>Feb</month>
            <day>22</day>
            <volume>131</volume>
            <issue>8</issue>
            <fpage>845</fpage>
            <page-range>845-854</page-range>
            <pub-id pub-id-type="pmid">29255070</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30096.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cines</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Blanchette</surname>
                <given-names>VS</given-names>
              </name>
            </person-group>
            <article-title>Immune thrombocytopenic purpura.</article-title>
            <source>N Engl J Med</source>
            <year>2002</year>
            <month>Mar</month>
            <day>28</day>
            <volume>346</volume>
            <issue>13</issue>
            <fpage>995</fpage>
            <page-range>995-1008</page-range>
            <pub-id pub-id-type="pmid">11919310</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30096.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Devos</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Meers</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Boeckx</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Gothot</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Deeren</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Chatelain</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Chatelain</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Devalet</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and management of PNH: Review and recommendations from a Belgian expert panel.</article-title>
            <source>Eur J Haematol</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>101</volume>
            <issue>6</issue>
            <fpage>737</fpage>
            <page-range>737-749</page-range>
            <pub-id pub-id-type="pmid">30171728</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30096.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Warkentin</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Greinacher</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Management of heparin-induced thrombocytopenia.</article-title>
            <source>Curr Opin Hematol</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>23</volume>
            <issue>5</issue>
            <fpage>462</fpage>
            <page-range>462-70</page-range>
            <pub-id pub-id-type="pmid">27380556</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30096.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>George</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Nester</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Syndromes of thrombotic microangiopathy.</article-title>
            <source>N Engl J Med</source>
            <year>2014</year>
            <month>Aug</month>
            <day>14</day>
            <volume>371</volume>
            <issue>7</issue>
            <fpage>654</fpage>
            <page-range>654-66</page-range>
            <pub-id pub-id-type="pmid">25119611</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30096.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>George</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Nester</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>McIntosh</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Syndromes of thrombotic microangiopathy associated with pregnancy.</article-title>
            <source>Hematology Am Soc Hematol Educ Program</source>
            <year>2015</year>
            <volume>2015</volume>
            <fpage>644</fpage>
            <page-range>644-8</page-range>
            <pub-id pub-id-type="pmid">26637783</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30096.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Provan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Stasi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Newland</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Blanchette</surname>
                <given-names>VS</given-names>
              </name>
              <name>
                <surname>Bolton-Maggs</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bussel</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Chong</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Cines</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Gernsheimer</surname>
                <given-names>TB</given-names>
              </name>
              <name>
                <surname>Godeau</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Grainger</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Greer</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Hunt</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Imbach</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Lyons</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>McMillan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rodeghiero</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sanz</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Tarantino</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Watson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kuter</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>International consensus report on the investigation and management of primary immune thrombocytopenia.</article-title>
            <source>Blood</source>
            <year>2010</year>
            <month>Jan</month>
            <day>14</day>
            <volume>115</volume>
            <issue>2</issue>
            <fpage>168</fpage>
            <page-range>168-86</page-range>
            <pub-id pub-id-type="pmid">19846889</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30096.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Neunert</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Crowther</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Solberg</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Crowther</surname>
                <given-names>MA</given-names>
              </name>
              <collab>American Society of Hematology</collab>
            </person-group>
            <article-title>The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia.</article-title>
            <source>Blood</source>
            <year>2011</year>
            <month>Apr</month>
            <day>21</day>
            <volume>117</volume>
            <issue>16</issue>
            <fpage>4190</fpage>
            <page-range>4190-207</page-range>
            <pub-id pub-id-type="pmid">21325604</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30096.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hviid</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>M&#x000f8;lgaard-Nielsen</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Corticosteroid use during pregnancy and risk of orofacial clefts.</article-title>
            <source>CMAJ</source>
            <year>2011</year>
            <month>Apr</month>
            <day>19</day>
            <volume>183</volume>
            <issue>7</issue>
            <fpage>796</fpage>
            <page-range>796-804</page-range>
            <pub-id pub-id-type="pmid">21482652</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30096.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nguyen</surname>
                <given-names>TG</given-names>
              </name>
              <name>
                <surname>Ward</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>To B or not to B cells-mediate a healthy start to life.</article-title>
            <source>Clin Exp Immunol</source>
            <year>2013</year>
            <month>Feb</month>
            <volume>171</volume>
            <issue>2</issue>
            <fpage>124</fpage>
            <page-range>124-34</page-range>
            <pub-id pub-id-type="pmid">23286939</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30096.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cines</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Bussel</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>How I treat idiopathic thrombocytopenic purpura (ITP).</article-title>
            <source>Blood</source>
            <year>2005</year>
            <month>Oct</month>
            <day>01</day>
            <volume>106</volume>
            <issue>7</issue>
            <fpage>2244</fpage>
            <page-range>2244-51</page-range>
            <pub-id pub-id-type="pmid">15941913</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30096.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scully</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kn&#x000f6;bl</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kentouche</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Rice</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Windyga</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schneppenheim</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kremer Hovinga</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Kajiwara</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fujimura</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Maggiore</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Doralt</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hibbard</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Martell</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ewenstein</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura.</article-title>
            <source>Blood</source>
            <year>2017</year>
            <month>Nov</month>
            <day>09</day>
            <volume>130</volume>
            <issue>19</issue>
            <fpage>2055</fpage>
            <page-range>2055-2063</page-range>
            <pub-id pub-id-type="pmid">28912376</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30096.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scully</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cataland</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Peyvandi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Coppo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kn&#x000f6;bl</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kremer Hovinga</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Metjian</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>de la Rubia</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pavenski</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Callewaert</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Biswas</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>De Winter</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zeldin</surname>
                <given-names>RK</given-names>
              </name>
              <collab>HERCULES Investigators</collab>
            </person-group>
            <article-title>Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura.</article-title>
            <source>N Engl J Med</source>
            <year>2019</year>
            <month>Jan</month>
            <day>24</day>
            <volume>380</volume>
            <issue>4</issue>
            <fpage>335</fpage>
            <page-range>335-346</page-range>
            <pub-id pub-id-type="pmid">30625070</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30096.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rathbone</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kaltenthaler</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Richards</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tappenden</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bessey</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cantrell</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS).</article-title>
            <source>BMJ Open</source>
            <year>2013</year>
            <month>Nov</month>
            <day>04</day>
            <volume>3</volume>
            <issue>11</issue>
            <fpage>e003573</fpage>
            <pub-id pub-id-type="pmid">24189082</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30096.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wijnsma</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Ter Heine</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Moes</surname>
                <given-names>DJAR</given-names>
              </name>
              <name>
                <surname>Langemeijer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Schols</surname>
                <given-names>SEM</given-names>
              </name>
              <name>
                <surname>Volokhina</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>van den Heuvel</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Wetzels</surname>
                <given-names>JFM</given-names>
              </name>
              <name>
                <surname>van de Kar</surname>
                <given-names>NCAJ</given-names>
              </name>
              <name>
                <surname>Br&#x000fc;ggemann</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>58</volume>
            <issue>7</issue>
            <fpage>859</fpage>
            <page-range>859-874</page-range>
            <pub-id pub-id-type="pmid">30758736</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30096.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sarno</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tufano</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Maruotti</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Martinelli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Balletta</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Russo</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Eculizumab in pregnancy: a narrative overview.</article-title>
            <source>J Nephrol</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>32</volume>
            <issue>1</issue>
            <fpage>17</fpage>
            <page-range>17-25</page-range>
            <pub-id pub-id-type="pmid">30159857</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30096.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stefanovic</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>The Extended Use of Eculizumab in Pregnancy and Complement Activation&#x0207b;Associated Diseases Affecting Maternal, Fetal and Neonatal Kidneys-The Future Is Now?</article-title>
            <source>J Clin Med</source>
            <year>2019</year>
            <month>Mar</month>
            <day>24</day>
            <volume>8</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">30909646</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30096.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>De Carolis</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>di Pasquo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rossi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Del Sordo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Buonomo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schiavino</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lanzone</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>De Stefano</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Fondaparinux in pregnancy: Could it be a safe option? A review of the literature.</article-title>
            <source>Thromb Res</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>135</volume>
            <issue>6</issue>
            <fpage>1049</fpage>
            <page-range>1049-51</page-range>
            <pub-id pub-id-type="pmid">25912931</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30096.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ciurzy&#x00144;ski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jankowski</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Pietrzak</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mazanowska</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Rzewuska</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kowalik</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pruszczyk</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Use of fondaparinux in a pregnant woman with pulmonary embolism and heparin-induced thrombocytopenia.</article-title>
            <source>Med Sci Monit</source>
            <year>2011</year>
            <month>May</month>
            <volume>17</volume>
            <issue>5</issue>
            <fpage>CS56</fpage>
            <page-range>CS56-9</page-range>
            <pub-id pub-id-type="pmid">21525816</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30096.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Efird</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Kockler</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>Fondaparinux for thromboembolic treatment and prophylaxis of heparin-induced thrombocytopenia.</article-title>
            <source>Ann Pharmacother</source>
            <year>2006</year>
            <season>Jul-Aug</season>
            <volume>40</volume>
            <issue>7-8</issue>
            <fpage>1383</fpage>
            <page-range>1383-7</page-range>
            <pub-id pub-id-type="pmid">16788093</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
